

Accu-Chek® Guide

System Evaluation



Accu-Chek® Guide: System Evaluation

Contents

The Accu-Chek® Guide System	1
Introduction	1
Main Features	2
System Specifications	4
Strip Technology	5
 Performance Evaluation	 6
Capillary Whole Blood Accuracy (Technician)	6
Capillary Whole Blood Accuracy (Patient)	9
Venous Whole Blood Accuracy	10
Arterial Whole Blood Accuracy	12
Neonatal Capillary Whole Blood Accuracy	14
System Precision—Intermediate Precision	16
System Precision—Repeatability	17
Impact of Hematocrit	18
Impact of Potentially Interfering Substances	20
 Conclusion	 27

The Accu-Chek® Guide System

Introduction

The Accu-Chek Guide system is a unique solution designed to meet the diverse needs of people with diabetes and their health care professionals. The system's features, such as the proprietary, oval, spill-resistant strip vial and an exciting new test strip design with a wide sample application area, provide surprisingly clever solutions to help make blood glucose testing easier. The easy-to-navigate meter interface and intuitive features support simple diabetes management. *Bluetooth®* connectivity offers quick insights virtually anytime and anywhere, as well as access to additional diabetes management support.

The system provides excellent accuracy and precision. The Accu-Chek Guide test strips have undergone a wide range of testing, including studies at external sites and extensive internal testing. Study results demonstrate that the test strips provide accurate and reliable blood glucose measurements under varied conditions, exceeding the performance requirements of the *ISO 15197:2013* standard. This document describes key features of the Accu-Chek Guide system and summarizes study results for accuracy, precision, hematocrit, and interfering substances.

Main Features

The Accu-Chek Guide system introduces our new blood glucose monitoring system. Along with the most valued features from previous Accu-Chek systems, the Accu-Chek Guide system includes innovations that simplify testing and contribute to successful diabetes management.

Test Strips

Spill-resistant oval strip vial

The new, clever strip vial design protects against spills and makes it easy to remove just one strip.

Easy edge dosing

The wide yellow application area is designed to enable dosing anywhere on the edge of the strip and is the largest dosing area among leading brands¹.

Fast test time

The test result appears in less than 4 seconds after dosing the strip.

Proven accuracy

The Accu-Chek Guide system fulfills the *ISO 15197:2013* standard and delivers even tighter accuracy for reliable results, making it Roche's most accurate system to-date.

Automatic coding

No coding is needed, resulting in fewer steps in testing.

Meter Design

Strip port light

A light appears when the strip is inserted to illuminate the dosing area for convenient testing in any lighting.

Test strip ejector

The strip ejector allows for quick and sanitary removal of used test strips.

Intuitive design and user-friendly navigation

The four-way button and user-friendly interface are designed for users who want a simple test, as well as users who desire more integrated features.

¹ Roche data on file

System Features

Test reminders

Up to four customizable test reminders and an after meal test reminder can be set on the meter to remind you when to test.

Adding comments to results

Comments can be added to results using various symbols to track particular situations, such as before meal, after meal, fasting, and bedtime.

Averages

The system calculates averages from results for the last 7, 14, 30 or 90 days. Averages can be viewed for particular situations (such as before meal and after meal).

Target ranges

The meter can display a symbol indicating whether a blood glucose reading is below, within, or above a selected target range.

Target percent

The meter can display the percentage of blood glucose results that are above, within, or below the target ranges.

Low and high results

The meter can display results for the past 30 days that fall above or below the target ranges set in the meter.

Pattern detection

The meter can highlight patterns of high or low readings within the past 7 days, a valuable tool for managing diabetes.

Failsafes

Before starting a test and during testing, the system performs extensive quality checks to ensure accurate results.

Bluetooth Connectivity

Bluetooth connectivity can wirelessly transmit results to the Accu-Chek Connect app, for convenient visualization and sharing with a healthcare professional.

USB connectivity

If desired, data can be transferred by USB cable from the meter to diabetes management software on a PC or on the web.

System Specifications

The tables below describe the specifications for the Accu-Chek Guide meter and test strips.

System Specifications

Category	Specification
Measurement principle	FAD glucose dehydrogenase (GDH), electrochemical
Range of measurement	0.6 to 33.3 mmol/L
Measuring time	Less than 4 seconds
Operating temperature	4°C to 45°C (39°F to 113°F)
Operating humidity	10 to 90%
Test strip expiration	18 months after production date Test strips remain stable up to the expiration date printed on test strip vial, even after opening (test strip container must be tightly closed after each test strip is removed).
Sample volume	0.6 µL
Hematocrit range	10 to 65%
Altitude	Up to 3,094 meters (10,150 feet) above sea level
Sample types	Capillary, venous, arterial, neonatal
Test sites	Fingertip, palm, forearm, upper arm
Reference method	Hexokinase with deproteinization, converted into plasma values according to IFCC recommendation

Meter Specifications

Category	Specification
Meter storage temperature	-25°C to 70°C (-13°F to 158°F)
Memory capacity	720 blood glucose results viewable on meter with time and date 32 control results with time and date
Automatic off	90 seconds
Power supply	Two 3-volt lithium batteries (coin cell type CR2032)
Display	LCD
Dimensions	80 mm length × 47 mm width × 20 mm height
Weight	Approximately 40 g (with batteries)
Construction	Hand-held
Protection class	III
Meter type	Suitable for continuous operation
Interfaces	USB: micro-B connector Continua Certified® to a Continua Certified manager



Strip Technology

Measurement Principle

When an Accu-Chek Guide test strip is inserted into the Accu-Chek Guide meter, a small alternating current (AC) is applied until the application of blood causes a sharp increase in the conductivity observed at the measurement and sample-sufficiency electrodes on the test strip. Both electrodes are used to assure an adequate sample has been applied.

Once a sufficient sample has been detected, the meter applies a series of AC voltages at four frequencies and reads the AC responses. These responses carry information about the sample type and environmental temperature, and also allow the system to perform various internal quality checks.

After the AC measurements are completed, a series of four ramped DC pulses are applied and the current is observed, which is proportionate to the glucose. The AC and DC information are then combined to provide a hematocrit and temperature compensated-glucose result.

Dosing Area

The new Accu-Chek Guide test strip design allows a small blood sample to be applied anywhere on the wide yellow edge of the test strip dosing area, which is three times larger than other leading brands².



² Roche data on file

Performance Evaluation

Capillary Whole Blood Accuracy (Technician)

Study Design


Technicians at one participating facility performed capillary finger sticks on patients. Two glucose test strips from three individual strip lots were dosed for each subject, for a total of 200 glucose meter results per lot. Meter results were compared to whole blood reference samples.

Acceptance Criteria (ISO 15197:2013):

- $\geq 95\%$ of the individual glucose measured values shall fall within ± 0.83 mmol/L of the reference results at glucose concentrations < 5.6 mmol/L or within $\pm 15\%$ at glucose concentrations ≥ 5.6 mmol/L.
- $\geq 99\%$ of individual glucose measured values shall fall within zones A and B of the Consensus Error Grid (CEG) for Type 1 diabetes.


Results (Pooled Strip Lots)

Subjects	100
Glucose Range (Reference)	2.2 to 30.7 mmol/L
Hematocrit Range (Reference)	32 to 51%



Zone	Description	Results
A	No effect on clinical action	100% (600/600)
B	Altered clinical action—little or no effect on clinical outcome	0% (0/600)
C	Altered clinical action—likely to affect clinical outcome	0% (0/600)
D	Altered clinical action—could have significant medical risk	0% (0/600)
E	Altered clinical action—could have dangerous consequences	0% (0/600)

Results (Strip Lot 1)




Results <5.6 mmol/L

Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.83 mmol/L
83.3% (50/60)	100.0% (60/60)	100.0% (60/60)

Results ≥ 5.6 mmol/L

Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 15\%$
75.0% (105/140)	100.0% (140/140)	100.0% (140/140)

Results (Strip Lot 2)




Results <5.6 mmol/L

Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.83 mmol/L
86.7% (52/60)	98.3% (59/60)	100.0% (60/60)

Results ≥ 5.6 mmol/L

Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 15\%$
90.0% (126/140)	100.0% (140/140)	100.0% (140/140)

Results (Strip Lot 3)



Results <5.6 mmol/L

Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.83 mmol/L
90.0% (54/60)	98.3% (59/60)	100.0% (60/60)

Results ≥ 5.6 mmol/L

Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 15\%$
87.9% (123/140)	100.0% (140/140)	100.0% (140/140)

Conclusion

100% of the data are within the bias requirements and 100% of the results fall within Zone A of the Consensus Error Grid, clearly exceeding the acceptance criteria. These data demonstrate that the system provides accurate results with capillary blood and results meet *ISO 15197:2013* requirements.

Capillary Whole Blood Accuracy (Patient)

Study Design


Patients at one facility were asked to read the labeling provided with the Accu-Chek Guide system, and to subsequently perform a finger stick and dose a test strip from one strip lot. The patients were given no instruction by a trained technician. The subject's results were compared to whole blood reference samples.

Acceptance Criteria (*ISO 15197:2013*):

- $\geq 95\%$ of the individual glucose measured values shall fall within ± 0.83 mmol/L of the reference results at glucose concentrations < 5.6 mmol/L and within $\pm 15\%$ at glucose concentrations ≥ 5.6 mmol/L.

Results

Subjects	100
Glucose Range (Reference)	4.6 to 25.6 mmol/L
Hematocrit Range (Reference)	34 to 50%



Results < 5.6 mmol/L

Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.83 mmol/L
66.7% (6/9)	100.0% (9/9)	100.0% (9/9)

Results ≥ 5.6 mmol/L

Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 15\%$
58.2% (53/91)	95.6% (87/91)	98.9% (90/91)

Conclusion

99% of the data are within the bias requirements, clearly exceeding the acceptance criteria. These data demonstrate that the untrained user can obtain accurate results with capillary blood, and results meet *ISO 15197:2013* requirements.

Venous Whole Blood Accuracy

Study Design


Technicians at one clinical site collected blood via venipuncture. Test strips from three independent lots were then dosed with the venous blood samples by the technicians. Two test strips were tested for each of three lots. Meter results were compared to whole blood reference samples.

Acceptance Criteria (CLSI POCT12-A3):

- $\geq 95\%$ of the individual results shall fall within ± 0.67 mmol/L of the reference results at glucose concentrations < 5.6 mmol/L and within $\pm 12.5\%$ at glucose concentrations ≥ 5.6 mmol/L.
- $\geq 98\%$ of the individual results shall fall within ± 0.83 mmol/L of the reference results at glucose concentrations < 4.2 mmol/L and within $\pm 20\%$ at glucose concentrations ≥ 4.2 mmol/L.

Results (Pooled Strip Lots)

Subjects	222
Glucose Range (Reference)	0.8 to 31.4 mmol/L
Hematocrit Range (Reference)	31 to 53%



Results < 5.6 mmol/L

Lot	Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.67 mmol/L
1	96.1% (73/76)	100.0% (76/76)	100.0% (76/76)
2	97.4% (74/76)	100.0% (76/76)	100.0% (76/76)
3	97.4% (74/76)	100.0% (76/76)	100.0% (76/76)

Results ≥ 5.6 mmol/L

Lot	Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 12.5\%$
1	92.9% (342/368)	99.7% (367/368)	100.0% (368/368)
2	91.6% (337/368)	100.0% (368/368)	100.0% (368/368)
3	96.7% (356/368)	99.7% (367/368)	99.7% (367/368)

Results <4.2 mmol/L

Lot	Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.83 mmol/L
1	100.0% (36/36)	100.0% (36/36)	100.0% (36/36)
2	100.0% (36/36)	100.0% (36/36)	100.0% (36/36)
3	97.2% (35/36)	100.0% (36/36)	100.0% (36/36)

Results ≥ 4.2 mmol/L

Lot	Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 15\%$	Within $\pm 20\%$
1	92.9% (379/408)	99.8% (407/408)	100.0% (408/408)	100.0% (408/408)
2	91.2% (372/408)	100.0% (408/408)	100.0% (408/408)	100.0% (408/408)
3	96.3% (393/408)	99.8% (407/408)	100.0% (408/408)	100.0% (408/408)

Conclusion

99.9% of the data for all lots combined are within the first bias requirement and 100% are within the second bias requirement, clearly exceeding the acceptance criteria. These data confirm that the Accu-Chek Guide system provides accurate results with venous blood samples.

Arterial Whole Blood Accuracy

Study Design


Technicians at one clinical site collected arterial blood using their standard operating procedure. Test strips from three independent lots were then dosed with the arterial blood samples by the technicians. Meter results were compared to whole blood reference samples.

Acceptance Criteria (CLSI POCT12-A3):

- $\geq 95\%$ of the individual results shall fall within ± 0.67 mmol/L of the reference results at glucose concentrations < 5.6 mmol/L and within $\pm 12.5\%$ at glucose concentrations ≥ 5.6 mmol/L.
- $\geq 98\%$ of the individual results shall fall within ± 0.83 mmol/L of the reference results at glucose concentrations < 4.2 mmol/L and within $\pm 20\%$ at glucose concentrations ≥ 4.2 mmol/L.

Results (Pooled Strip Lots)

Subjects	214
Glucose Range (Reference)	1.0 to 25.1 mmol/L
Hematocrit Range (Reference)	18 to 59%



Results < 5.6 mmol/L

Lot	Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.67 mmol/L
1	88.9% (32/36)	100.0% (36/36)	100.0% (36/36)
2	88.9% (32/36)	100.0% (36/36)	100.0% (36/36)
3	86.1% (31/36)	100.0% (36/36)	100.0% (36/36)

Results ≥ 5.6 mmol/L

Lot	Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 12.5\%$
1	90.4% (161/178)	99.4% (177/178)	100.0% (178/178)
2	89.3% (159/178)	98.3% (175/178)	100.0% (178/178)
3	87.6% (156/178)	98.9% (176/178)	100.0% (178/178)

Results <4.2 mmol/L

Lot	Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.83 mmol/L
1	100.0% (1/1)	100.0% (1/1)	100.0% (1/1)
2	100.0% (1/1)	100.0% (1/1)	100.0% (1/1)
3	100.0% (1/1)	100.0% (1/1)	100.0% (1/1)

Results ≥ 4.2 mmol/L

Lot	Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 15\%$	Within $\pm 20\%$
1	89.7% (191/213)	99.5% (212/213)	100.0% (213/213)	100.0% (213/213)
2	88.7% (189/213)	98.6% (210/213)	100.0% (213/213)	100.0% (213/213)
3	86.9% (185/213)	98.6% (210/213)	100.0% (213/213)	100.0% (213/213)

Conclusion

100% of the data for all lots combined are within both sets of bias requirements, clearly exceeding the acceptance criteria. These data confirm that the Accu-Chek Guide system provides accurate results with arterial blood samples.

Neonatal Capillary Whole Blood Accuracy

Study Design

Studies were conducted to assess the accuracy of the Accu-Chek Guide system with neonatal capillary blood samples. Technicians at one participating facility performed capillary heel sticks on newborns (less than 30 days old) and dosed test strips from three independent strip lots. Meter results were compared to whole blood reference samples.

Acceptance Criteria (*CLSI POCT12-A3*):


- $\geq 95\%$ of the individual results shall fall within ± 0.67 mmol/L of the reference results at glucose concentrations < 5.6 mmol/L and within $\pm 12.5\%$ at glucose concentrations ≥ 5.6 mmol/L.
- $\geq 98\%$ of the individual results shall fall within ± 0.83 mmol/L of the reference results at glucose concentrations < 4.2 mmol/L and within $\pm 20\%$ at glucose concentrations ≥ 4.2 mmol/L.

Additional Criteria:

- The mean bias shall not be significantly higher than 0.28 mmol/L nor significantly lower than -0.28 mmol/L for all results < 2.8 mmol/L.

All Results (Pooled Strip Lots)

Subjects	201 (Lot 1 & Lot 2) 202 (Lot 3)
Glucose Range (Reference)	0.7 to 28.2 mmol/L
Hematocrit Range (Reference)	19 to 62%



Results < 5.6 mmol/L

Lot	Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.67 mmol/L
1	92.8% (167/180)	100.0% (180/180)	100.0% (180/180)
2	90.0% (162/180)	100.0% (180/180)	100.0% (180/180)
3	82.3% (149/181)	100.0% (181/181)	100.0% (181/181)

Results ≥ 5.6 mmol/L

Lot	Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 12.5\%$
1	90.5% (19/21)	100.0% (21/21)	100.0% (21/21)
2	81.0% (17/21)	100.0% (21/21)	100.0% (21/21)
3	81.0% (17/21)	100.0% (21/21)	100.0% (21/21)


Results <4.2 mmol/L

Lot	Within ± 0.28 mmol/L	Within ± 0.56 mmol/L	Within ± 0.83 mmol/L
1	97.4% (111/114)	100.0% (114/114)	100.0% (114/114)
2	95.6% (109/114)	100.0% (114/114)	100.0% (114/114)
3	90.4% (104/115)	100.0% (115/115)	100.0% (115/115)

Results ≥ 4.2 mmol/L

Lot	Within $\pm 5\%$	Within $\pm 10\%$	Within $\pm 15\%$	Within $\pm 20\%$
1	79.3% (69/87)	100.0% (87/87)	100.0% (87/87)	100.0% (87/87)
2	75.9% (66/87)	100.0% (87/87)	100.0% (87/87)	100.0% (87/87)
3	63.2% (55/87)	98.9% (86/87)	100.0% (87/87)	100.0% (87/87)

Results Below 2.8 mmol/L (Pooled Strip Lots)



Results <2.8 mmol/L

N	Mean Bias (mmol/L)
109	-0.1

Conclusion

100% of the data for all lots combined are within both sets of bias requirements, clearly exceeding the acceptance criteria. In addition, results under 2.8 mmol/L show minimal mean bias. These data confirm that the Accu-Chek Guide system provides accurate results with neonatal blood samples, including samples with very low glucose levels (less than 2.8 mmol/L).

System Precision—Intermediate Precision

Study Design

Intermediate precision of the Accu-Chek Guide system was assessed using aqueous control solutions. Ten vials of test strips from each of three lots were allocated per target glucose level. Ten replicates per vial were collected and the overall SD or CV (based on glucose level) was calculated using results from all vials and strip lots.

Control Solutions:

- **Low:** 1.7 to 3.3 mmol/L
- **Mid:** 5.5 to 7.4 mmol/L
- **High:** 14.0 to 19.0 mmol/L

Acceptance Criteria:

- Standard deviation (SD) shall be ≤ 0.17 mmol/L at glucose concentrations < 5.6 mmol/L
- Coefficient of variation (CV) shall be $\leq 3.0\%$ at glucose concentrations ≥ 5.6 mmol/L

Results (Pooled Strip Lots)

Level	Mean	SD	CV
Low	2.5	0.1	--
Mid	6.5	0.2	2.4
High	16.5	0.4	2.3

Conclusion

All acceptance criteria are clearly met. In fact, with all strip lots pooled, the SD value is 0.1 mmol/L for glucose concentrations less than 5.6 mmol/L, and CV values are at or below 2.4% for concentrations above 5.6 mmol/L. These data indicate that the Accu-Chek Guide system provides precise results with control solutions.

System Precision—Repeatability

Study Design

Repeatability of the Accu-Chek Guide system was assessed using venous blood samples. Ten vials of test strips from each of three lots were allocated per target glucose level. Ten replicates per vial were collected and the overall SD or CV (based on glucose level) was calculated using results from all vials and strip lots.

Venous Blood Samples:

- **Level 1:** 1.7 to 2.8 mmol/L
- **Level 2:** 2.8 to 6.1 mmol/L
- **Level 3:** 6.2 to 8.3 mmol/L
- **Level 4:** 8.4 to 13.9 mmol/L
- **Level 5:** 13.9 to 22.2 mmol/L

Acceptance Criteria:

- Standard deviation (SD) shall be ≤ 0.22 mmol/L at glucose concentrations < 5.6 mmol/L
- Coefficient of variation (CV) shall be $\leq 4.0\%$ at glucose concentrations ≥ 5.6 mmol/L

Results (Pooled Strip Lots)

Level	Mean	SD	CV
1	2.3	0.1	--
2	4.5	0.1	--
3	7.3	0.1	2.1
4	11.5	0.3	2.6
5	18.3	0.5	2.6

Conclusion

All acceptance criteria are clearly met. In fact, with all strip lots pooled, the SD values are 0.1 mmol/L for glucose concentrations less than 5.6 mmol/L, and CV values are at or below 2.6% for concentrations above 5.6 mmol/L. These data indicate that the Accu-Chek Guide system provides precise results with venous blood.

Impact of Hematocrit

Study Design

Five levels of glycolized venous blood were tested with various hematocrit levels to determine the impact of hematocrit on the performance of the Accu-Chek Guide system. Meter results were compared to a sample at nominal hematocrit (42%).

Target Glucose Levels:

- 2.2 mmol/L
- 4.4 mmol/L
- 7.0 mmol/L
- 11.1 mmol/L
- 18.0 mmol/L

Hematocrit Levels:



- 10%, 15%, 20%, 25%, 30%, 35%
- 45%, 50%, 55%, 60%, 65%

Acceptance Criteria (ISO 15197:2013):



- Mean bias (to reference glucose) shall not exceed ± 0.56 mmol/L to the nominal hematocrit sample (42%) mean bias (to reference glucose) at glucose concentrations < 5.6 mmol/L.
- Mean bias (to reference glucose) shall not exceed $\pm 10\%$ to the nominal hematocrit sample (42%) mean bias (to reference glucose) at glucose concentrations ≥ 5.6 mmol/L.

Results



Strip Lot 1



Strip Lot 2



Strip Lot 3



Conclusion

Data from all three lots confirm that the Accu-Chek Guide system supports a claimed hematocrit range of 10 to 65% and meets *ISO 15197:2013* requirements.

Impact of Potentially Interfering Substances

The Accu-Chek Guide system has been thoroughly evaluated with potential interfering substances. Substances were tested at concentrations described by the Clinical Lab Standard Institute in document *EP7-A2 — Interference Testing in Clinical Chemistry; Approved Guideline*, when available. Testing was conducted according to the *ISO 15197:2013* standard. Many of the endogenous and exogenous compounds were evaluated at concentrations three or more times therapeutic plasma concentrations. Each medication and metabolite was evaluated at the following target glucose levels to ensure accuracy:

- 2.8 to 5.6 mmol/L
- 13.9 to 19.4 mmol/L

Test results indicate that the system provides accurate results in the presence of the substances tested, generally well beyond the therapeutic or physiologic range. See the table below for a list of the substances evaluated, along with the concentration tested and the upper therapeutic concentration. All concentrations are in terms of mmol/L unless noted otherwise.

Note: Concentrations below are shown in exponential notation, in order to display values in a uniform manner across the wide range of concentrations. To convert these values:

- **Positive Exponent:** Move the decimal point to the right by the number of places specified by the exponent (number after E).
Acetone Highest Concentration Tested: 1.03E+01
 $1.03 \times 10 = 10.3 \text{ mmol/L}$
- **Negative Exponent:** Move the decimal point to the left by the number of places specified by the exponent (number after E).
Acetone Upper Therapeutic Concentration: 1.70E-01
 $1.70 / 10 = 0.17 \text{ mmol/L}$
- **00 Exponent:** Use the stated value with no adjustment.
Acetaminophen Highest Concentration Tested: 1.32E+00
 $= 1.32 \text{ mmol/L}$

Substance	Highest Concentration Tested (mmol/L)	Upper Therapeutic Concentration (mmol/L)
Acarbose	9.30E-01	1.56E-04
Acetaminophen	1.32E+00	3.44E-01
Acetazolamide	2.70E-01	8.56E-02
Acetone	1.03E+01	1.70E-01
N-Acetyl-L-Cysteine	1.23E+00	3.07E-01
N-Acetylprocainamide	5.40E-01	3.61E-02
Acetylsalicylic Acid	3.33E+00	5.55E-02
Acyclovir	2.20E-01	9.77E-02
Albumin	7.60E-01	8.20E-01
Albuterol	1.05E+00	6.30E-05

Substance	Highest Concentration Tested (mmol/L)	Upper Therapeutic Concentration (mmol/L)
Allopurinol	3.70E-01	1.47E-01
Aminocaproic Acid	3.05E+00	1.53E+00
Amiodarone	7.00E-02	2.17E-02
Amitriptyline	4.00E-02	5.78E-04
Amoxapine	3.00E-03	2.96E-04
Amoxicillin	1.64E+01	4.93E-02
Ampicillin	1.50E-01	7.16E-02
Astemizole	2.00E-02	2.18E-04
Atorvastatin	1.79E-03	4.48E-04
Atropine	3.00E-02	6.92E-04
Benserazide	2.00E-02	5.05E-03
Bile Acids	4.00E-02	1.70E-02
Bilirubin (conjugated)	1.03E+00	3.40E-03
Bilirubin (unconjugated)	1.03E+00	1.90E-02
Buspirone	3.00E-02	5.19E-06
Caffeine	5.20E-01	1.85E-01
Calcium Chloride	5.00E+00	2.75E+00
Captopril	2.00E-02	4.05E-03
Carbamazepine	1.30E-01	6.35E-02
Beta-Carotene	1.00E-02	3.70E-03
Cefaclor	5.40E+00	6.32E-02
Cefadroxil	2.80E-01	9.91E-02
Ceftriaxone	1.80E+00	1.01E+00
Cephalexin	9.20E-01	1.86E-01
Cephalothin	5.06E+00	1.91E+00
Cetirizine	2.00E-02	3.73E-03
Chenodeoxycholic Acid	8.00E-02	2.50E-03
Chlorothiazide	9.13E-02	3.04E-02
Chlorpropamide	2.89E+00	7.95E-01
Cholesterol	1.30E+01	7.75E+00
Cholic Acid	6.00E-02	1.50E-03
Cimetidine	4.00E-01	3.96E-02
Citalopram	1.85E-02	5.58E-03
Citric Acid	1.56E+00	1.60E-01
Clindamycin	9.00E-02	4.00E-02
Clonidine	9.00E-02	2.80E-05
Creatinine	2.65E+00	1.30E-01
Cyclophosphamide	1.44E+00	7.01E-01
L-Cysteine	4.10E-01	1.16E-01

Substance	Highest Concentration Tested (mmol/L)	Upper Therapeutic Concentration (mmol/L)
L-Cystine	2.08E+00	1.17E-01
Desipramine	4.00E-03	2.55E-03
Dexamethasone	3.06E-02	1.13E-02
Dextromethorphan	4.00E-02	1.90E-05
Diclofenac	1.70E-01	2.70E-02
Dicumarol	1.80E-01	1.75E-01
Digoxin	1.00E-02	1.70E-05
Diltiazem	4.40E-01	7.24E-04
Diphenhydramine	3.00E-02	1.01E-03
Dipyron	3.30E-01	undetermined
Disopyramide	1.50E-01	1.65E-02
L-Dopa	1.00E-01	1.27E-02
Dopamine	1.00E-02	1.35E-03
Doxazosin	2.00E-02	2.24E-04
Doxycycline	6.00E-02	1.35E-02
EDTA dipotassium	8.90E+00	1.13E-03
EDTA disodium calcium	4.81E+00	1.13E-03
Enalapril	1.60E-01	7.25E-04
Ephedrine	6.00E-02	5.00E-05
Equilin	5.60E-01	1.86E-02
Erythromycin	8.20E-01	6.27E-02
Estradiol	4.00E-03	9.18E-09
Estrone	4.00E-02	3.70E-07
Ethanol	7.60E+01	4.34E+01
Ethosuximide	1.77E+00	7.08E-01
Ethyl Acetoacetate	1.54E+00	1.50E-01
Ethylene Glycol	8.10E-01	2.42E-02
Famotidine	2.00E-02	2.41E-03
Felodipine	1.30E-01	2.50E-05
Fenofibrate	1.40E-01	4.16E-02
Fenoprofen	8.30E-01	2.68E-01
Flecainide	2.00E-02	4.13E-03
5-Fluorocytosine	2.32E+00	5.27E-01
Fluoxetine	3.90E-01	1.53E-03
Flurbiprofen	2.00E-01	6.55E-02
Fluticasone	2.25E-03	8.41E-07
Fructose	1.39E+01	3.30E-01
Furosemide	1.80E-01	1.60E-02
Galactose	1.67E+01	3.33E+00

Substance	Highest Concentration Tested (mmol/L)	Upper Therapeutic Concentration (mmol/L)
Galactose-1-Phosphate	1.20E-01	7.00E-03
Gamma Globulins	3000 mg/dL	1600 mg/dL
Gemfibrozil	6.00E-01	1.84E-01
Gentamicin	8.00E-02	2.22E-02
Gentisic Acid	1.20E-01	3.24E-02
Glimepiride	2.00E-02	1.12E-03
Glipizide	1.80E-01	2.24E-03
Glucosamine	2.51E+01	1.30E-01
Glutathione (reduced)	2.00E-01	2.00E-02
Glyburide	3.00E-02	4.86E-04
Glycerol	1.09E+00	1.96E-01
Hemoglobin	100 g/L	25 g/L
Heparin (Li)	80000 U/L	1100 U/L
Heparin (Na)	80000 U/L	1100 U/L
Hydrochlorothiazide	2.00E-02	1.26E-03
Hydrocortisone	3.00E-02	6.00E-04
DL-Beta-Hydroxybutyric Acid	9.61E+00	2.70E-01
Hydroxychloroquine Sulfate	1.20E-01	3.90E-04
Ibandronic Acid	2.00E-02	1.00E-03
Ibuprofen	2.43E+00	3.54E-01
Indomethacin	1.40E-01	1.23E-02
Insulin	20 U/dL	0.004 U/dL
Isoniazid	3.60E-01	1.46E-01
Kanamycin	1.86E-01	6.19E-02
Lactic Acid	1.11E+01	2.20E+00
Lactitol	2.90E+00	undetermined
Lactose	2.90E-01	1.50E-02
Lecithin	1.60E+01	1.19E+01
Lidocaine	1.00E-01	2.13E-02
Lisinopril	2.00E-02	2.02E-04
Loratadine	3.00E-02	9.00E-05
Lovastatin	1.00E-02	1.73E-04
Magnesium Sulfate	2.16E+00	2.16E-01
Maltitol	5.90E-01	undetermined
Maltose	1.52E+00	3.51E+00
D-Mannitol	3.30E+01	undetermined
D-Mannose	5.60E-01	undetermined
Metaproterenol	9.00E-02	6.00E-05
Metformin	3.88E+00	3.10E-02

Substance	Highest Concentration Tested (mmol/L)	Upper Therapeutic Concentration (mmol/L)
Methimazole	2.00E-02	7.27E-03
Methyl Dopa	7.00E-02	3.55E-02
Methylhydroxyprogesterone	1.45E+00	2.00E-08
Metoclopramide	1.49E-02	2.50E-03
Metoprolol Tartrate	3.00E-02	1.87E-03
Mexiletine	6.00E-02	1.39E-02
Misoprostol	2.00E-02	2.12E-06
Nadolol	6.00E-02	1.10E-04
Naproxen	4.35E+00	5.21E-01
Neostigmine Bromide	1.00E-02	1.15E-03
Nicotine	1.20E-01	1.99E-03
Nifedipine	1.16E+00	5.66E-04
Nitrofurantoin	1.70E-01	2.98E-03
Nordoxepin	1.90E-01	3.09E-04
D-Norpropoxyphene	2.00E-02	8.10E-03
Nortriptyline	1.00E-02	1.43E-03
Norverapamil	2.00E-02	4.55E-04
Oleic Acid	1.24E+00	3.90E-02
Omeprazole	2.00E-02	8.11E-03
Oxalic Acid	2.22E+00	2.00E-02
Palmitic Acid	5.85E+00	2.00E-01
D-Penicillamine	1.60E-01	4.42E-02
Penicillin G	4.20E-01	3.40E-02
Phenelzine	4.00E-02	1.50E-05
L-Phenylalanine	3.03E+00	2.10E-01
Phenytoin	4.00E-01	7.93E-02
Pindolol	2.00E-02	3.26E-04
Pioglitazone	1.40E-01	4.45E-03
Piroxicam	9.00E-02	2.90E-02
Polysorbate 80	3.00E-03	undetermined
Potassium Chloride	6.70E+00	3.10E+00
Prednisolone	1.11E-02	1.11E-03
Primidone	2.30E-01	8.71E-02
Probenecid	2.11E+00	5.22E-01
Procainamide	4.30E-01	6.80E-02
Propranolol	4.00E-02	1.29E-03
Pseudoephedrine	6.00E-02	6.66E-03
Pyridinealdoxime Methiodide (PAM)	9.40E-01	1.50E-02
Pyridostigmine	2.21E-02	1.88E-03

Substance	Highest Concentration Tested (mmol/L)	Upper Therapeutic Concentration (mmol/L)
Pyridoxine	1.80E-01	undetermined
Pyruvic Acid	4.50E-01	1.02E-01
Quinine Sulfate	1.50E-01	5.00E-02
Ramipril	9.00E-02	1.25E-04
Ranitidine	6.40E-01	1.11E-02
Repaglinide	1.10E-01	8.80E-04
Rifampicin	1.00E-01	1.94E-02
Rosiglitazone	1.10E-01	1.82E-03
Salicylic Acid	4.34E+00	6.89E-02
Sodium Bicarbonate	4.00E+01	2.90E-03
D-Sorbitol	3.85E+00	2.40E-03
Stearic Acid	5.30E-01	9.80E-02
Streptomycin	2.10E-01	1.48E-01
Sucrose	1.46E+01	1.80E-03
Terfenadine	5.30E-01	9.54E-06
Tetracycline	2.30E-01	1.80E-02
Theophylline	1.39E+00	1.11E-01
Thioridazine	1.10E-01	1.05E-02
L-Thyroxine	6.00E-02	1.84E-04
Tobramycin	8.00E-02	2.35E-02
Tolazamide	6.42E+00	4.82E-02
Tolbutamide	3.70E+00	6.77E-01
Trazodone	5.00E-02	1.32E-02
Triamterene	2.40E-01	7.70E-04
Trimethoprim	2.10E-01	4.82E-02
DL-Tyrosine	1.33E+00	1.30E+00
Urea	1.00E+02	6.30E+00
Uric Acid	1.40E+00	4.80E-01
Valproic Acid	3.01E+00	7.35E-01
Vancomycin	1.40E-01	2.76E-02
Verapamil	2.00E-02	1.17E-03
Vitamin B12	1.00E-02	6.20E-08
Vitamin E	4.60E-01	4.60E-02
Voluven	800 mg/dL	800 mg/dL
Warfarin	3.20E-01	8.11E-02
Xylitol	1.32E+01	7.90E-03

The following compounds were found to be interfering substances when tested with the Accu-Chek Guide system.

Substance	Accu-Chek Guide System Accuracy Threshold (mmol/L)
Ascorbic Acid ³	> 0.28
Lipidemia (Triglycerides) ⁴	> 20.30
Xylose ⁵	> 0.67

³ The system should not be used during intravenous administration of ascorbic acid.

⁴ Lipemic samples (triglycerides) in excess of 20.30 mmol/L may produce elevated results.

⁵ The system should not be used during xylose absorption test.

Conclusion

The data presented demonstrate the capability of the Accu-Chek Guide meter and test strips and indicate that the system is compliant with the performance requirements of *ISO 15197:2013*. With a less than 4-second test, minimal sample volume, and spill-resistant vial, the Accu-Chek Guide system is an easy-to-use tool for monitoring of blood glucose levels. Along with these features, the system's accurate and reliable test results make it a best-in-class blood glucose monitoring system.

www.accu-chek.com.au • Accu-Chek Enquiry Line: 1800 251 816

For people with diabetes. Use only as directed. Consult your healthcare professional for advice. Accu-Chek lancing devices are for single patient use only. The same device must not be used for multiple patients.

ACCU-CHEK and ACCU-CHEK GUIDE are trademarks of Roche. ©2017 Roche Diabetes Care. All Rights Reserved. All other trademarks are the property of their respective owners.

CONTINUA, the CONTINUA logos and CONTINUA CERTIFIED are trademarks, service marks, or certification marks of the Continua Health Alliance. CONTINUA is a registered trademark in some, but not all, countries in which this product is distributed.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Roche is under license.

Roche Diabetes Care Australia Pty Ltd. 24-32 Lexington Drive, Bella Vista NSW 2153, Australia. ABN 69 602 140 278. July 2017.



ACCU-CHEK®